These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 14576652)

  • 21. Features of Patients With Crohn's Disease and Hidradenitis Suppurativa.
    Kamal N; Cohen BL; Buche S; Delaporte E; Colombel JF
    Clin Gastroenterol Hepatol; 2016 Jan; 14(1):71-9. PubMed ID: 25956836
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Infliximab for severe gastrointestinal bleeding in Crohn's disease.
    Ando Y; Matsushita M; Kawamata S; Shimatani M; Fujii T; Okazaki K
    Inflamm Bowel Dis; 2009 Mar; 15(3):483-4. PubMed ID: 18668673
    [No Abstract]   [Full Text] [Related]  

  • 23. Systematic review of the efficacy and adverse events associated with infliximab treatment of hidradenitis suppurativa in patients with coexistent inflammatory diseases.
    Machet L; Samimi M; Delage M; Paintaud G; Maruani A
    J Am Acad Dermatol; 2013 Oct; 69(4):649-50. PubMed ID: 24034373
    [No Abstract]   [Full Text] [Related]  

  • 24. Paradoxical effect of infliximab in a patient with hidradenitis suppurativa.
    Gori A; Rossari S; Bruscino N; Tripo L
    Dermatol Ther; 2012; 25(4):376-8. PubMed ID: 22950564
    [No Abstract]   [Full Text] [Related]  

  • 25. Severe refractory hidradenitis suppurativa in an HIV-positive patient successfully treated with infliximab.
    Alecsandru D; Padilla B; Izquierdo JA; Fernández-Cruz E; Sánchez-Ramón S
    Arch Dermatol; 2010 Dec; 146(12):1343-5. PubMed ID: 21173317
    [No Abstract]   [Full Text] [Related]  

  • 26. A case of hidradenitis suppurativa refractory to anti-TNFalpha therapy in a patient with Crohn's disease.
    Koilakou S; Karapiperis D; Tzathas C
    Am J Gastroenterol; 2010 Jan; 105(1):231-2. PubMed ID: 20054324
    [No Abstract]   [Full Text] [Related]  

  • 27. Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. A BALANCING VIEW: lifetime channeling of infliximab for crohn's disease.
    Hanauer SB
    Am J Gastroenterol; 2005 Jul; 100(7):1438-9. PubMed ID: 15984961
    [No Abstract]   [Full Text] [Related]  

  • 28. The cutting edge. Severe hidradenitis suppurativa treated with adalimumab.
    Moul DK; Korman NJ
    Arch Dermatol; 2006 Sep; 142(9):1110-2. PubMed ID: 16982997
    [No Abstract]   [Full Text] [Related]  

  • 29. Experiences with a long-term treatment of a massive gluteal acne inversa with infliximab in Crohn's disease.
    Goertz RS; Konturek PC; Naegel A; Janka R; Amann K; Maennlein G; Wein A; Hahn EG; Boxberger F
    Med Sci Monit; 2009 Jan; 15(1):CS14-8. PubMed ID: 19114971
    [TBL] [Abstract][Full Text] [Related]  

  • 30. QUIZ HQ 40. Perineal abscesses and fistulas--always a mark of Crohn's disease?
    Gheorghe C; Cotruta B; Trifu V; Grasu M; Gheorghe L
    J Gastrointestin Liver Dis; 2007 Sep; 16(3):307-8, 342. PubMed ID: 17944061
    [No Abstract]   [Full Text] [Related]  

  • 31. Is there a role for infliximab in the current therapy of hidradenitis suppurativa? A report of three treated cases.
    Moschella SL
    Int J Dermatol; 2007 Dec; 46(12):1287-91. PubMed ID: 18173525
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of infliximab in the treatment of Crohn's disease in children and adolescents.
    Hyams JS
    J Pediatr Gastroenterol Nutr; 2001 Sep; 33 Suppl 1():S36-9. PubMed ID: 11685974
    [No Abstract]   [Full Text] [Related]  

  • 33. Verrucous Plaques of the Buttocks, Perineum, and Umbilicus.
    Bittar JM; Burton K; Rahnama S
    Gastroenterology; 2019 Dec; 157(6):1480-1482. PubMed ID: 31310743
    [No Abstract]   [Full Text] [Related]  

  • 34. [Recommendations for the use of infliximab (Remicade) in Crohn's disease. GETECCU 2001].
    Domènech E; Esteve-Comas M; Gomollón F; Hinojosa J; Obrador A; Panés J; Gassull MA;
    Gastroenterol Hepatol; 2002 Mar; 25(3):162-9. PubMed ID: 11864540
    [No Abstract]   [Full Text] [Related]  

  • 35. Treatment of severe recalcitrant hidradenitis suppurativa with adalimumab.
    Harde V; Mrowietz U
    J Dtsch Dermatol Ges; 2009 Feb; 7(2):139-41. PubMed ID: 19371236
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Maintenance therapy with biologic agents for Crohn's disease: impact of scheduled maintenance therapy with infliximab].
    Endo K; Shiga H; Kakuta Y; Takahashi S; Kinouchi Y; Shimosegawa T
    Nihon Shokakibyo Gakkai Zasshi; 2011 Mar; 108(3):401-9. PubMed ID: 21389661
    [No Abstract]   [Full Text] [Related]  

  • 37. Canadian Association of Gastroenterology Clinical Practice Guidelines: the use of infliximab in Crohn's disease.
    Panaccione R; Fedorak RN; Aumais G; Bernstein CN; Bitton A; Croitoru K; Enns R; Feagan B; Fishman M; Greenberg G; Griffiths A; Marshall JK; Rasul I; Sadowski D; Seidman E; Steinhart H; Sutherland L; Walli E; Wild G; Williams CN; Zachos M;
    Can J Gastroenterol; 2004 Aug; 18(8):503-8. PubMed ID: 15372114
    [No Abstract]   [Full Text] [Related]  

  • 38. SAPHO syndrome associated with hidradenitis suppurativa successfully treated with infliximab and methotrexate.
    De Souza A; Solomon GE; Strober BE
    Bull NYU Hosp Jt Dis; 2011; 69(2):185-7. PubMed ID: 22035400
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prolonged duration of response to infliximab in early pediatric Crohn's disease.
    Kugathasan S
    J Pediatr Gastroenterol Nutr; 2001 Sep; 33 Suppl 1():S40-3. PubMed ID: 11685975
    [No Abstract]   [Full Text] [Related]  

  • 40. Safe use of infliximab for the treatment of fistulizing Crohn's disease during pregnancy within 3 months of conception.
    Angelucci E; Cocco A; Viscido A; Caprilli R
    Inflamm Bowel Dis; 2008 Mar; 14(3):435-6. PubMed ID: 18050300
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.